STML stock forecast
Our latest prediction for Stemline Therapeutics, Inc.'s stock price was made on the Aug. 14, 2019 when the stock price was at 14.80$.
In the short term (2weeks), STML's stock price should underperform the market by -0.57%. During that period the price should oscillate between -9.34% and +11.23%.
In the medium term (3months), STML's stock price should underperform the market by -0.92%. During that period the price should oscillate between -22.09% and +30.13%.Get email alerts
Create a solid portfolio with STML
About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
At the moment the company generates 43M USD in revenues.
On its last earning announcement, the company reported a loss of -1.83$ per share.
The book value per share is 2.63$
Three months stock forecastAug. 14, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|